These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 10363995)

  • 1. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
    Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
    Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
    Yoshinari T; Matsumoto M; Arakawa H; Okada H; Noguchi K; Suda H; Okura A; Nishimura S
    Cancer Res; 1995 Mar; 55(6):1310-5. PubMed ID: 7882328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
    Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM
    Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
    Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y
    Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
    Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
    Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
    Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
    Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a DNA topoisomerase IIalpha gene rearrangement in adriamycin-resistant P388 leukemia: expression of a fusion messenger RNA transcript encoding topoisomerase IIalpha and the retinoic acid receptor alpha locus.
    McPherson JP; Brown GA; Goldenberg GJ
    Cancer Res; 1993 Dec; 53(24):5885-9. PubMed ID: 8261398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I.
    Yoshinari T; Ohkubo M; Fukasawa K; Egashira S; Hara Y; Matsumoto M; Nakai K; Arakawa H; Morishima H; Nishimura S
    Cancer Res; 1999 Sep; 59(17):4271-5. PubMed ID: 10485471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506.
    Pilch B; Allemand E; Facompré M; Bailly C; Riou JF; Soret J; Tazi J
    Cancer Res; 2001 Sep; 61(18):6876-84. PubMed ID: 11559564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
    Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
    Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
    Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.
    Kapoor R; Slade DL; Fujimori A; Pommier Y; Harker WG
    Oncol Res; 1995; 7(2):83-95. PubMed ID: 7579731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
    Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
    J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
    Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
    Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110.
    Yoshinari T; Yamada A; Uemura D; Nomura K; Arakawa H; Kojiri K; Yoshida E; Suda H; Okura A
    Cancer Res; 1993 Feb; 53(3):490-4. PubMed ID: 8381047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone.
    Harker WG; Slade DL; Parr RL; Holguin MH
    Cancer Res; 1995 Nov; 55(21):4962-71. PubMed ID: 7585537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole- 5,7(6H)-dione (NB-506): its potent antitumor activities in mice.
    Arakawa H; Iguchi T; Morita M; Yoshinari T; Kojiri K; Suda H; Okura A; Nishimura S
    Cancer Res; 1995 Mar; 55(6):1316-20. PubMed ID: 7882329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitor structure but independent of cell death.
    Fu Q; Kim SW; Chen HX; Grill S; Cheng YC
    Mol Pharmacol; 1999 Apr; 55(4):677-83. PubMed ID: 10101025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
    Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
    Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
    Feldhoff PW; Mirski SE; Cole SP; Sullivan DM
    Cancer Res; 1994 Feb; 54(3):756-62. PubMed ID: 8306338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.